CPT® Code 87337

1. Indications

The CPT® Code 87337 is indicated for the detection of antigens related to the Entamoeba histolytica group in patients who may be experiencing symptoms associated with this parasitic infection. The following conditions and symptoms warrant the use of this test:

• Abdominal Pain Patients presenting with unexplained abdominal pain may require testing to rule out infections caused by Entamoeba histolytica.
• Diarrhea Individuals experiencing persistent or severe diarrhea, particularly when associated with other gastrointestinal symptoms, may be tested for the presence of this parasite.
• Liver Abscess The test may be indicated in cases where a liver abscess is suspected, as E. histolytica can lead to this serious complication.
• Acute Colitis Patients with symptoms of acute colitis may be tested to determine if E. histolytica is the causative agent.
• Travel History Individuals with a recent travel history to endemic areas where E. histolytica is prevalent may be tested if they exhibit gastrointestinal symptoms.

2. Procedure

The procedure for conducting the test associated with CPT® Code 87337 involves several key steps to ensure accurate detection of the Entamoeba histolytica antigens in a fecal sample. The following procedural steps are outlined:

• Sample Collection A fecal sample is collected from the patient. This sample can either be placed in a fixative to preserve the integrity of the specimen or sent fresh to the laboratory for immediate processing. Proper collection techniques are essential to avoid contamination and ensure reliable results.
• Preparation of the Sample Once the sample reaches the laboratory, it is prepared for analysis. This may involve homogenizing the fecal material and diluting it as necessary to facilitate the immunoassay process.
• Immunoassay Technique The laboratory technician selects an appropriate immunoassay technique, such as EIA, ELISA, FIA, or IMCA, based on the laboratory's protocols. The specific antibodies that target the Entamoeba histolytica antigens are added to the sample, allowing for the binding of the antigen-antibody complex.
• Detection of Antigen In the case of EIA and ELISA, a secondary enzyme-labeled antibody is introduced, which binds to the antigen-antibody complex. A chromogenic reaction occurs, resulting in a color change that can be quantitatively measured. For FIA, a fluorescent compound is used to detect the binding, while IMCA utilizes chemiluminescent substances to identify and quantify the complex through light emission.
• Result Interpretation The results of the test are assessed qualitatively or semi-quantitatively based on the intensity of the color change or fluorescence. The laboratory reports the findings to the requesting physician, who will interpret the results in the context of the patient's clinical presentation.

3. Post-Procedure

After the completion of the test associated with CPT® Code 87337, the following post-procedure considerations are important:

Patients may not require any specific post-procedure care following the fecal sample collection, as this is a non-invasive procedure. However, it is essential for healthcare providers to communicate the results of the test to the patient promptly. If the test indicates the presence of Entamoeba histolytica antigens, further clinical evaluation and management may be necessary, which could include additional diagnostic testing or treatment options based on the severity of the infection and the patient's overall health status. Patients should be advised to report any worsening symptoms or new gastrointestinal issues to their healthcare provider. Additionally, education on preventive measures, such as proper food and water hygiene, may be beneficial to reduce the risk of future infections.